Emisphere Technologies Inc. said Tuesday that its Phase III trial of oral heparin failed to show superiority to Aventis SA's injected Lovenox in preventing deep-vein thrombosis in patients undergoing total hip replacement surgery. (BioWorld Today)
Athersys Inc. completed a private placement totaling $16.2 million to be used to continue about a dozen projects, which focus on oncology, the central nervous system and inflammation. (BioWorld Today)
Athersys Inc. completed a private placement totaling $16.2 million to be used to continue about a dozen projects, which focus on oncology, the central nervous system and inflammation. (BioWorld Today)
